Taken together our results indicate that FAP(hF1) UCAR T-cell treatment of tumor-bearing mice results in significant FAP+ cells depletion and reduction in stromal physical barrier in the tumor microenvironment, confirming their onsite anti-CAF activity. The gene discussed is FAP; the disease is neoplasm.